MicroVue C5a EIA*

1.800.874.1517

English | Chinese

Intended Use	For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number	A021 (US), A025 (XUS)
Price	$700.00 (U.S. List Price)
Size	1 Kit (96 well)
Application	ELISA

Buy Now Request Info

Description

For Research Use Only in the United States. Not for use in diagnostic procedures.

The MicroVue C5a Enzyme Immunoassay measures the amount of C5a-des-Arg present in human serum, plasma and other biological or experimental samples.

Complement protein C5 is unique to the terminal complement pathway and under normal conditions is cleaved by a C5 convertase to C5a and C5b as a result of activation of the classical, alternative or lectin complement pathway.

Research has shown that elevated levels of C5a have been associated with pathogenesis of a variety of disease states including myocardial infarction, stroke and kidney injury. The role of C5a in the pathogenesis of malaria and other infectious diseases as well as sepsis is likewise well documented.

The MicroVue C5a Enzyme Immunoassay measures the concentration of C5a in human plasma, serum and other experimental samples. It uses a proprietary monoclonal antibody to a neo-epitope on C5a to capture C5a in solid phase. The trapped C5a is then detected by HRP-labeled antibodies to C5a antigens. This test provides a quantitative measurement of C5a levels and is designed for investigations into the role and status of terminal complement pathway activation in numerous clinical and research settings.

References:

13 References

Arbesu I, Bucsaiova M, Fischer MB, Mannhalter C. Platelet-borne complement proteins and their role in platelet–bacteria interactions. J Thromb Haemost 2016; 14: 2241–52.

Wang G, Chen F, Banda NK, Holers VM, Wu L, Moghimi SM and Simberg D (2016) Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. Front. Immunol. 7:418. doi: 10.3389/fimmu.2016.00418

TScambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, et al. (2015) The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLOS ONE 10(2): e0114856.

Merel M. Koopmans, Matthijs C. Brouwer, Madelijn Geldhoff, Mercedes Valls Seron, Judith Houben, Arie van der Ende, Diederik van de Beek, Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis, In BBA Clinical, Volume 1, 2014, Pages 44-51, ISSN 2214-6474

Brouwer MC, Baas F, van der Ende A, van de Beek D (2013) Genetic Variation and Cerebrospinal Fluid Levels of Mannose Binding Lectin in Pneumococcal Meningitis Patients. PLOS ONE 8(5): e65151.

Agarwal, S., Specht, C. A., Huang, H., Ostroff, G. R., Ram, S., Rice, P. A., & Levitz, S. M. (2011). Linkage Specificity and Role of Properdin in Activation of the Alternative Complement Pathway by Fungal Glycans. mBio, 2(5), e00178–11. http://doi.org/10.1128/mBio.00178-11

Arumugam T.V., Tang S.C., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death, PNAS 104(35) 14104-14109, 2007.

Haas P, van Strijp J, Anaphylatoxins: Their role in bacterial infections, Immunol Res 37(3):161-175, 2007.

Guo R.F., Ward, P.D. Role of C5a in Inflammatory Responses, Annu. Rev. Immunol 23:821-852, 2005.

Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction, Cardiovascular Res 53:31-47, 2002.

Sheerin N.S., Sacks S.H., Leaked protein and interstitial damage in the kidney: is complement the missing link, Clin Exp Immunol 130:1-3, 2002.

Hugli, T.E. Biochemistry and biology of anaphylatoxins, Complement 3:111, 1986.

Tack B.F., Morris S.C., Prahl J.W. Fifth component of human complement: purification from plasma and polypeptide chain structure, Biochemistry 18(8): 1490-1497, 1979.